Merck KGaA Keeps Powder Dry On Licensing Deals
Pleased With Potential Of Pipeline
After doing a number of healthcare deals in 2021, it looks as though Merck KGaA will keep M&A activity to a minimum for the division this year, focusing instead on advancing its own promising candidates for cancer, multiple sclerosis and lupus.
You may also be interested in...
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.